The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system.

There was a highly significant increase in the proportion of OVA-specific CD8 + T cells in the spleens of mice treated with Ad5-OVA plus 5-FU over mice treated with Ad5-OVA alone ( Fig. 2 A ).

also in 132,142 other papers